Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.

Lawrence D Sher,Jonathan Corren,Ian D, Pavord,Nadia Daizadeh,Arman Altincatal,Xavier Soler,Michel Djandji,Amr Radwan,Juby A Jacob-Nara,Yamo Deniz,Paul J Rowe

The Journal of asthma : official journal of the Association for the Care of Asthma（2023）

引用 0|浏览24

暂无评分

摘要

Dupilumab efficacy was sustained for up to 3 years in patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma, with or without evidence of allergic asthma.ClinicalTrials.gov identifier: NCT02134028.

查看译文

关键词

ACQ-5,IgE,exacerbation,long-term,lung function,pre-bronchodilator FEV1,type 2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要